

REMARKS

Claims 1, 3-5, 11-14 and 23-25 are pending. Claims 2, 4, 6-10 and 15-22 are canceled. Claims 1, 11 and 23 are amended. No new matter is added. Reconsideration is requested.

Support for the amending language of Claims 1, 11 and 23 maybe found in the specification at paragraph 60.

Applicants thank the Examiner for the rejoinder of claims to the generic formula set forth in Claim 1; and for the withdrawal of the previous rejections. The withdrawal of Claims 19-22 from consideration is noted.

Claim 22 has been objected to in the recitation of "tTGase". The objection is made moot by the cancellation of the claim. For clarity, independent claims 11 and 23 have been amended to recite the term "tissue transglutaminase" before the phrase "tTGase".

Claims 1, 3-5, 11-14 and 23-25 have been rejected under 35 U.S.C. 112, second paragraph. The Office Action states that the claims are indefinite, and states that it is unclear what "effective dose" is contemplated. Independent claims 1, 11 and 23 have been amended and recite an effective dose of 0.01 mg to 500 mg/kg body weight per day, as set forth in the specification at paragraph 60.

Withdrawal of the rejection is requested.

CONCLUSION


Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, he is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number STAN-258CIP.

Respectfully submitted,

Date: May 9 , 2007

By:



Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, CA 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231